Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. MarketScreener Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Australia backs Pfizer virus vaccine over AstraZeneca for under-50s

04/08/2021 | 09:19am EDT
FILE PHOTO: Oxford/AstraZeneca's COVID-19 vaccine at a vaccination centre in Antwerp

CANBERRA/SYDNEY (Reuters) - Australia said on Thursday it now recommends people under 50 should get Pfizer's COVID-19 vaccine in preference to AstraZeneca's shot, a policy shift that it warned would hold up its inoculation campaign.

The move, a day after European regulators reiterated they had found possible links between AstraZeneca's shot and reports of very rare cases of blood clots, is a huge hurdle for Australia's programme, which had relied on that vaccine.

Australia's Chief Medical Officer, Paul Kelly, told reporters the risk of clots was extremely low.

"It's only been found in the first dose of the AstraZeneca vaccine, usually within 4 to 10 days after that vaccine. But it is serious, and it can cause up to a 25% death rate when it occurs," he said.

Australia would advise health providers to only give a first dose of the AstraZeneca vaccine to adults younger than 50 when the benefit clearly outweighs the risks, he added.

Italy and Britain on Wednesday joined other countries in suggesting age limits for AstraZeneca's vaccine. But the European regulators reaffirmed the importance of that shot in protecting people against COVID-19.

Those who have already had a first AstraZeneca dose without any serious adverse events "can safely be given their second dose," Kelly said.

Prime Minister Scott Morrison said the updated advice will delay Australia's inoculation timetable, but it was too soon to say when Canberra would now vaccinate its adult population.

"There will be a recalibration of how the programme will need to be adjusted," Morrison told reporters in Canberra.

Australia has ordered 20 million doses of the Pfizer vaccine and Morrison said Canberra was in talks to increase the order.

Authorities will continue to give the AstraZeneca vaccine to people over 70. Those over 50 who opt for the Pfizer vaccine will have to wait, the government said.

Australia - which had planned to use the AstraZeneca vaccine for the vast majority of its near 26 million population - expected to give all adults at least one shot by October.

But its immunisation campaign was already heavily behind schedule.

It had pledged to administer at least 4 million first doses by the end of March, but could only deliver 670,000, with the government blaming the delay on supply issues in Europe.

It had been looking to ramp up the immunisation effort, underpinned by plans to make 50 million doses of AstraZeneca vaccine in Australia, produced by CSL Ltd.

Australia began vaccinations much later than some other nations because of its few infections, which stand at just under 29,400, with 909 deaths, since the pandemic began.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access)

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps)

(Reporting by Colin Packham and Jonathan Barrett; Editing by Michael Perry, Clarence Fernandez and Andrew Heavens)

By Colin Packham and Jonathan Barrett


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -0.27% 7380 Delayed Quote.0.76%
CSL LIMITED 0.29% 269.07 End-of-day quote.-4.98%
All news about ASTRAZENECA PLC
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
AQ
04/16ASTRAZENECA  : Doctors say lowering age cutoff for AstraZeneca vaccine makes sen..
AQ
04/16Consumer Cos Climb On Reopening Optimism -- Consumer Roundup
DJ
04/16Health Care Up After Strong Start to Earnings Season -- Health Care Roundup
DJ
04/16Vaccine Manufacturing Issues Force Moderna to Cut Supplies to Canada, U.K.
DJ
04/16No Causal Link Found So Far Between J&J's Covid-19 Vaccine and Blood-Clot Cas..
DJ
04/16ASTRAZENECA  : German's IDT to make 10M AstraZeneca vaccine doses in 2021
AQ
04/16ASTRAZENECA  : Covid-19 - Lagos, Kano Lead As Nigeria Vaccinates Over 1m Persons
AQ
04/16MARKET CHATTER : Johnson & Johnson Reportedly Asked Other COVID-19 Vaccine Produ..
MT
04/16ASTRAZENECA  : Australia's Medicine Watchdog Links Woman's Death To AstraZeneca ..
MT
More news
Financials (USD)
Sales 2021 30 805 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
NameTitle
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
ASTRAZENECA PLC0.76%133 897
JOHNSON & JOHNSON3.09%422 260
ROCHE HOLDING AG0.16%289 178
PFIZER INC.2.15%209 739
NOVARTIS AG-3.73%197 072
MERCK & CO., INC.-5.29%194 049